首页 | 本学科首页   官方微博 | 高级检索  
     


Mapping the binding sites of challenging drug targets
Affiliation:1. Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA;2. Department of Chemistry, Boston University, Boston, MA 02215, USA;3. Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, USA;4. Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY, USA;1. Center for Theoretical Biological Physics, Rice University, Houston, TX, USA;2. Department of Physics and Astronomy, Rice University, Houston, TX, USA;3. Department of Chemistry, Rice University, Houston, TX, USA;4. Department of Biosciences, Rice University, Houston, TX, USA;1. Dipartimento di Scienze e Tecnologie Agro-Alimentari, Alma Mater Studiorum – Università di Bologna, Piazza Goidanich 60, 47521 Cesena, Italy;2. Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine – CIRMMP, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Italy;3. CERM – Magnetic Resonance Center, Università Degli Studi di Firenze, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Italy;4. Dipartimento di Chimica, Università Degli Studi di Firenze, Via Della Lastruccia 3, 50019 Sesto Fiorentino, Italy;1. The European Radiation Synchrotron Facility (ESRF), Grenoble, France;2. Bioengineering Department, Northeastern University, Boston, MA, USA;1. Department of Chemistry, University of Illinois at Urbana-Champaign, USA;2. Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, USA;3. Center for the Physics of the Living Cell, University of Illinois at Urbana-Champaign, USA
Abstract:
An increasing number of medically important proteins are challenging drug targets because their binding sites are too shallow or too polar, are cryptic and thus not detectable without a bound ligand or located in a protein–protein interface. While such proteins may not bind druglike small molecules with sufficiently high affinity, they are frequently druggable using novel therapeutic modalities. The need for such modalities can be determined by experimental or computational fragment based methods. Computational mapping by mixed solvent molecular dynamics simulations or the FTMap server can be used to determine binding hot spots. The strength and location of the hot spots provide very useful information for selecting potentially successful approaches to drug discovery.
Keywords:Beyond rule of five compounds  Inhibitors of protein–protein interactions  Allosteric sites  Cryptic sites  Mixed solvent molecular dynamics
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号